Tiratricol (Synonyms: 3,3',5-Triiodothyroacetic acid)

Name: Tiratricol
Brand: MedChemExpress
SKU: HY-B1201
Rating: 4.5 (1 reviews)

Cat. No.: HY-B1201 Purity: 99.60%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Tiratricol is an orally available thyroid hormone analog that inhibits pituitary thyroid-stimulating hormone secretion. Tiratricol is an intracellular toxin neutralizer that inhibits LPS and lipid A cytotoxicity with IC₅₀s of 20 μM and 32 μM, respectively. Tiratricol reduces TNF production in lipopolysaccharide-stimulated macrophages. Tiratricol also has antiviral activity and is an inhibitor of yellow fever virus (Flavivirus). It can bind to the RdRp domain of the viral NS5 protein to hinder YFV replication..

For research use only. We do not sell to patients.

Tiratricol Chemical Structure

CAS No. : 51-24-1

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 47	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 47	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	USD 42	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Tiratricol:

Tiratricol (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All TNF Receptor Isoform Specific Products:

View All Isoforms

TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HEK-293T	EC₅₀	0.37 μM Compound: TRIAC	Agonist activity at recombinant human pFA-CMV fused PPARgamma expressed in HEK293T cells transfected with pFR-luciferase plasmid and pRL-SV40 plasmid incubated for 14 to 16 hrs by dual glo luciferase reporter gene assay Agonist activity at recombinant human pFA-CMV fused PPARgamma expressed in HEK293T cells transfected with pFR-luciferase plasmid and pRL-SV40 plasmid incubated for 14 to 16 hrs by dual glo luciferase reporter gene assay	[PMID: 32356658]
HEK-293T	EC₅₀	12 μM Compound: TRIAC	Agonist activity at recombinant human pFA-CMV fused RXRalpha LBD expressed in HEK293T cells transfected with pFR-luciferase plasmid and pRL-SV40 plasmid incubated for 14 to 16 hrs by dual glo luciferase reporter gene assay Agonist activity at recombinant human pFA-CMV fused RXRalpha LBD expressed in HEK293T cells transfected with pFR-luciferase plasmid and pRL-SV40 plasmid incubated for 14 to 16 hrs by dual glo luciferase reporter gene assay	[PMID: 32356658]
LNCaP	IC₅₀	28.3 μM Compound: 5, TRIAC	Binding affinity to human androgen receptor BF3 F673R mutant stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis Binding affinity to human androgen receptor BF3 F673R mutant stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis	[PMID: 22047606]
LNCaP	IC₅₀	34.8 μM Compound: 5, TRIAC	Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis	[PMID: 22047606]
LNCaP	IC₅₀	42.8 μM Compound: 5, TRIAC	Binding affinity to human androgen receptor BF3 R840A mutant stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis Binding affinity to human androgen receptor BF3 R840A mutant stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis	[PMID: 22047606]
U2OS	IC₅₀	6.9 μM Compound: TRIAC	Inhibition of HA-tagged human NTCP expressed in human U2OS cells assessed as reduction in [14C]taurocholate uptake preincubated for 10 mins followed by [14C] taurocholate addition and further incubation for 10 mins by scintillation counting method Inhibition of HA-tagged human NTCP expressed in human U2OS cells assessed as reduction in [14C]taurocholate uptake preincubated for 10 mins followed by [14C] taurocholate addition and further incubation for 10 mins by scintillation counting method	[PMID: 31439379]

In Vitro

Tiratricol (10, 40 μM; 24 h) dose-dependently inhibits YFV infection of Huh-7 cells and also reduces the expression of viral non-structural protein (NS3) ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	Huh-7 cells
Concentration:	0.625, 2.5, 10, and 40 μM
Incubation Time:	24 h
Result:	Remarkably suppressed the viral proteins of NS1, NS2B, NS3, prM and capsid.

In Vivo

Tiratricol (0.2 mg/kg/day; po; 6 days) pretreatment can prevent YFV infection in mice and improve mouse health^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice infected with YFV^[2]
Dosage:	0.2 mg/kg/day
Administration:	po; day 0–6 post infection (dpi) or from 2 days before infection to 6 dpi
Result:	Significantly reduce virus titers and protein expression. Restored body weight and improved the survival rate of YFV-infected mice by 40%.

Clinical Trial

Molecular Weight

621.93

Formula

C₁₄H₉I₃O₄

CAS No.

51-24-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 42 mg/mL (67.53 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6079 mL	8.0395 mL	16.0790 mL
5 mM	0.3216 mL	1.6079 mL	3.2158 mL
10 mM	0.1608 mL	0.8039 mL	1.6079 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.60%

Select Batch:

Data Sheet (272 KB) SDS (392 KB)

COA (244 KB) LCMS (101 KB)

Handling Instructions (2659 KB)

References

[1]. Ren H, et al. Tiratricol inhibits yellow fever virus replication through targeting viral RNA-dependent RNA polymerase of NS5. Antiviral Res. 2023 Nov;219:105737. [Content Brief]

[2]. Cascales L, et al. Tiratricol neutralizes bacterial endotoxins and reduces lipopolysaccharide-induced TNF-alpha production in the cell. Chem Biol Drug Des. 2008 Oct;72(4):320-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6079 mL	8.0395 mL	16.0790 mL	40.1975 mL
	5 mM	0.3216 mL	1.6079 mL	3.2158 mL	8.0395 mL
	10 mM	0.1608 mL	0.8039 mL	1.6079 mL	4.0197 mL
	15 mM	0.1072 mL	0.5360 mL	1.0719 mL	2.6798 mL
	20 mM	0.0804 mL	0.4020 mL	0.8039 mL	2.0099 mL
	25 mM	0.0643 mL	0.3216 mL	0.6432 mL	1.6079 mL
	30 mM	0.0536 mL	0.2680 mL	0.5360 mL	1.3399 mL
	40 mM	0.0402 mL	0.2010 mL	0.4020 mL	1.0049 mL
	50 mM	0.0322 mL	0.1608 mL	0.3216 mL	0.8039 mL
	60 mM	0.0268 mL	0.1340 mL	0.2680 mL	0.6700 mL

Tiratricol Related Classifications

Endocrinology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tiratricol51-24-13,3',5-Triiodothyroacetic acidThyroid Hormone ReceptorFlavivirusTNF ReceptorTHRTumor Necrosis Factor ReceptorTNFRInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Tiratricol (Synonyms: 3,3',5-Triiodothyroacetic acid)

Customer Review

Other Forms of Tiratricol:

Tiratricol Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All TNF Receptor Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Tiratricol Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Tiratricol Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report